The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites.
The key role of estrogens on osteoblastic cell function is well documented; however, the role of progesterone (P) and synthetic progestins remains controversial. While several reports indicate that P has no significant effects on bone cells, a number of clinical studies have shown that 19-norprogestins restore postmenopausal bone loss. The mechanisms by which 19-norprogestins induce estrogen-like effects on bone cells are not fully understood. To assess whether the actions of 19-norprogestins on osteoblasts are mediated by their non-phenolic metabolites, we studied the effects of norethisterone (NET), levonorgestrel (LNG), and two of their A-ring reduced derivatives upon cell proliferation and differentiation in neonatal rat osteoblasts. Osteoblast function was assessed by determining cell DNA, cell-associated osteocalcin and calcium content, alkaline phosphatase activity, and mineral deposition. P failed to induce changes on osteoblasts, while NET and LNG exerted a number of actions. The most striking finding was that the 3beta,5alpha- and 3alpha,5alpha-tetrahydro derivatives of NET and LNG induced osteoblast proliferation and differentiation with higher potency than those exerted by their parent compounds, mimicking the effects of estradiol. Interestingly, osteoblast differentiation and mineral deposition induced by NET and LNG were abolished by finasteride, a 5alpha-reductases inhibitor, while the potent effect on osteoblast proliferation induced by progestin derivatives was abolished by a steroidal antiestrogen. Results demonstrate that A-ring reduced derivatives of NET and LNG exhibit intrinsic estrogen-like potency on rat osteoblasts, offering a plausible explanation for the mechanism of action of 19-norprogestins in bone restoration in postmenopausal women and providing new insights for hormone replacement therapy research.
Enríquez
Juana
J
Department of Reproductive Biology, Instituto Nacional de Ciencias Médicas y Nutrición S. Zubirán (INCMNSZ), Mexico City 14000, Mexico.
Lemus
Ana Elena
AE
Chimal-Monroy
Jesús
J
Arzate
Higinio
H
García
Gustavo A
GA
Herrero
Bertha
B
Larrea
Fernando
F
Pérez-Palacios
Gregorio
G
D058891:5-alpha Reductase Inhibitors; D000818:Animals; D002113:Calcification, Physiologic; D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D005260:Female; D018120:Finasteride / Q000494:pharmacology; D000077267:Fulvestrant; D006801:Humans; D016912:Levonorgestrel / Q000378:metabolism / Q000494:pharmacology; D009640:Norethindrone / Q000378:metabolism / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D015675:Osteocalcin / Q000378:metabolism; D010636:Phenols / Q000378:metabolism; D045167:Progesterone Congeners / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D058891:5-alpha Reductase Inhibitors; D020847:Estrogen Receptor Modulators; D010636:Phenols; D045167:Progesterone Congeners; D015675:Osteocalcin; D000077267:Fulvestrant; D004958:Estradiol; D018120:Finasteride; D016912:Levonorgestrel; D002118:Calcium; D009640:Norethindrone